Piperine as a modulator of cancer hallmarks: mechanistic insights and therapeutic potential
Frontiers in Oncology · 07.04.2026 · 16
DOI: 10.3389/fonc.2026.1810344 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 07.04.2026. Verfasst von Wamidh H Talib und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Allied Medical Sciences, Applied Science Private University, Amman, Jordan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cancer processing relies on a range of biological capabilities referred to as cancer hallmarks. There is growing interest in natural bioactive compounds that have the potential to modulate these hallmarks. Piperine, an alkaloid isolated from Piper nigrum and Piper longum , has shown various biological effects, including anticancer activity in preclinical studies.
Methods
The present review summarizes in vitro and in vivo studies regarding the impact of piperine on various cancer attributes. The available Literature was thoroughly analyzed to identify evidence for the molecular basis by which piperine modulates cell growth, apoptosis, angiogenesis, invasion and metastasis, inflammation, and oxidative stress in various types of cancer.
Discussion
The compound has been shown to inhibit the proliferation of various cancer cell lines and may enhance the effectiveness of conventional chemotherapy agents by improving drug bioavailability and reducing resistance. Moreover, piperine may target several hallmarks of cancer that influence cancer progression and metastasis, including angiogenesis, sustained proliferation, genomic instability, resistance to cell death, immune evasion, and disrupted redox homeostasis. These multifaceted effects of piperine are believed to be mediated through the modulation of signaling pathways such as NF-κB, PI3K/Akt, MAPK, and STAT3. Although these results are encouraging, the therapeutic use of piperine is limited by its poor solubility, low bioavailability, and lack of clinical research.
Conclusion
Piperine is a promising multitarget compound that can influence important cancer characteristics in preclinical studies. Nevertheless, additional research is needed to overcome formulation issues, assess toxicity, and conduct well-structured clinical trials to confirm its potential as an effective anticancer treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Allied Medical Sciences, Applied Science Private University, Amman, Jordan.
- Department of Applied Biotechnology, College of Biotechnology, Al-Qasim Green University, Babylon, Iraq.
- Medical and Clinical Laboratory Technology, Faculty of Allied Medical Sciences, Applied Science Private University, Amman, Jordan.
- Faculty of Pharmacy, Al-Azhar University of Gaza, Gaza, Palestine.
- Department of Clinical Nutrition and Dietetics, Applied Science Private University, Amman, Jordan.
- Faculty of Health and Life Sciences, Inti International University, Nilai, Malaysia.
Zitieren
APA
Talib, W. H., Kadhim, M. J., Al Junaidi, H. S., BenBraiek, A., Mohanna, W. M., Alfaleet, Y. A., Hadi, R. W., Law, D., Prashant, A., Takács, K., & Soós, I. (2026). Piperine as a modulator of cancer hallmarks: mechanistic insights and therapeutic potential. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1810344
Vancouver
Talib WH, Kadhim MJ, Al Junaidi HS, BenBraiek A, Mohanna WM, Alfaleet YA, et al. Piperine as a modulator of cancer hallmarks: mechanistic insights and therapeutic potential. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1810344
BibTeX
@article{Talib2026,
author = {Talib, Wamidh H and Kadhim, Mohanad Jawad and Al Junaidi, Hadeel Shaher and BenBraiek, Assia and Mohanna, Ward M and Alfaleet, Yara A and Hadi, Rawan W and Law, Douglas and Prashant, Akila and Takács, Krisztina and Soós, Imre},
title = {Piperine as a modulator of cancer hallmarks: mechanistic insights and therapeutic potential},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1810344}
}
EUVIMED